Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shenduqing is a Traditional Chinese Medicine (TCM) formulation developed by the Hospital of Chengdu University of Traditional Chinese Medicine, primarily administered as a retention enema. It is specifically indicated for the treatment of non-dialysis patients with chronic kidney disease (CKD) stages 3 to 5. As a hospital-made preparation, it is designed to improve TCM symptom scores and stabilize renal function by promoting the intestinal excretion of metabolic wastes such as serum creatinine and urea nitrogen. The formulation typically leverages the 'intestinal clearance' theory in TCM to reduce the accumulation of uremic toxins and mitigate systemic inflammation, thereby delaying the progression of renal failure in patients who have not yet reached the stage of requiring dialysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shenduqing.